Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. - Wikidata - wikimedia - TriplyDB

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.

http://www.wikidata.org/entity/Q40718678

about

MUC1 and MUC4: switching the emphasis from large to small Mucins in cancer: function, prognosis and therapy Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms SMAD2 and SMAD7 involvement in the post-translational regulation of Muc4 via the transforming growth factor-beta and interferon-gamma pathways in rat mammary epithelial cells Where now for anti-EGF receptor therapies in colorectal cancer?ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Muc4/MUC4 functions and regulation in cancer Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers.In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer Primary trastuzumab resistance: new tricks for an old drug.New developments in the treatment of metastatic gastric cancer: focus on trastuzumab Resistance to HER2-targeted therapies: a potential role for FOXM1.Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.Role of mucins in the skin during benign and malignant conditions.HER2 therapy: molecular mechanisms of trastuzumab resistance.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer Autophagy: friend or foe in breast cancer development, progression, and treatment Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.Target points in trastuzumab resistance Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma.New developments in the treatment of HER2-positive breast cancer

P2860

Q24599141-A5229EA4-CA8C-4102-9DE8-8CA1AB487290 Q24633765-99A68012-329B-4C2E-947B-A8E7B3D2D13B Q26764879-8FC6FD64-98B2-40C3-8149-4249136F0396 Q27346475-43DE4C84-2350-4096-A27F-F7142C32A130 Q28566287-B94F25F2-A661-43E0-8CC6-17D900AE5159 Q28572073-1C2E3543-DF4A-4B4C-9DDD-E24CE201B1AE Q31038305-378DDF96-0595-47BB-927A-1637B261D74B Q33601653-D082F6D7-99A0-46A4-A239-0D4C7367D07D Q33674729-E6F9AA1D-E18F-4498-B5CE-D9F0EAD10914 Q33828409-E338EC45-CD94-4E2F-B9C3-5C726ACCFAA4 Q33873317-102D8985-6D74-4F44-AFC1-AFB5945F0F35 Q33938044-5C0F3D03-88EE-4DE2-9787-3C18C08ED02E Q34140167-0C20C053-2764-4F30-920F-71E12A8A1CFA Q34165045-2115F520-96CE-42C9-82CB-08C067D913A6 Q34308692-464DF227-ED76-4522-BCF0-224EC21F5653 Q34334146-91F4D6AC-464F-4BD1-B45E-895E4C9878C3 Q34355748-819B7EDD-AFBC-4AC2-BDEA-2546DCE9ED34 Q34428742-5A049F52-EDF0-4EF9-9590-460B6F52FDB5 Q34483555-EB4C54ED-48F1-4118-A879-5637C2E7FA8F Q34570753-B6425163-B649-4FDA-9E6E-41594F9A7B86 Q34610251-3D6AB401-D062-4DBD-B8FF-DC3C1946438A Q34883258-F72FA1D4-C3B0-4D3E-9A7F-5C43132E74B2 Q34955355-B52217E0-0AD4-4E26-AAC0-75797522CC1B Q35591518-47D88D63-1EF8-4293-8BB7-60859F92937A Q35591546-1138CA9D-7D5D-4AE6-87AC-AD55DC1EE580 Q35596376-DE59E34D-1883-414C-A03F-9F1D7BB4C0AA Q35633712-091DA83C-4FE8-4222-B5A5-9434FAFA4EE3 Q35684440-CBBC4D44-DBD7-4DD9-B6AE-3A2EFFB71831 Q35684456-BA210F38-4104-45FC-9A62-A4F03B28D81D Q35786749-31D2F8E7-317A-4B63-8A2E-EF53CFA70917 Q35821286-277AE8EC-E18B-412F-8E7D-E92135EE49A4 Q36088788-59C61775-BB2E-4E15-B9F1-2E4DE343A60F Q36114852-23055018-C1C1-467D-AE00-885FF8A39AAA Q36127379-3025CFE9-AD65-4803-94E6-E34916F79F22 Q36205260-B9C95F61-8764-4254-BC9F-CBD08E85C8D2 Q36415623-3883DC7D-939D-4441-855C-C1E423E2312A Q36440214-F79F3689-D5E7-4406-B409-5587C6BBE07A Q36727464-46DE7E95-2D56-484D-BBA4-FB876F52E87D Q36751896-198108E4-BA3F-4E4F-9C56-44892949C15D Q37016382-91C348FC-B155-42E9-9373-2EF920184DF7

P2860

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.

http://www.wikidata.org/entity/Q40718678

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Rat Muc4 (sialomucin complex) ...... nism for herceptin resistance.

@en

type

label

Rat Muc4 (sialomucin complex) ...... nism for herceptin resistance.

@en

prefLabel

Rat Muc4 (sialomucin complex) ...... nism for herceptin resistance.

@en

P1433

Q40718678-EF748C88-0B24-4637-BD29-CE237733163C

P1476

Q40718678-595007BB-981A-440C-92A6-4D229CC8EE1A

P2093

Q40718678-1B66C0BC-3CCD-4704-8CE4-1A53A0E5ECFE

Q40718678-3E595661-F85A-462A-B14F-E0BB5640F449

Q40718678-6ED79432-5F66-4493-A451-D1FD5B321906

Q40718678-B42DF994-372A-4091-8A24-31C6ED427A79

Q40718678-DA0DBFC7-1F0E-4368-93D8-CDA45EA8F3B3

Q40718678-E5403E11-14BF-4701-ADF7-FCB1C5E2EE7D

Q40718678-FEAC28A1-DEDC-445B-8E28-3A0E48EAA5AD

P2860

Q40718678-0CD8CD4C-3BD8-4125-A5E2-D73C8BCEEAE7

Q40718678-197736B4-C785-4AE1-AFD1-186EAC515BF1

Q40718678-29781DC0-9CDD-44BC-96BB-75778F4E0EE7

Q40718678-2D55B570-6623-4D3D-810B-71D1E6F21F61

Q40718678-2EF793AC-24FF-4ADB-9EA1-4A043A97DF0D

Q40718678-3F734FAA-1C51-4B93-9805-6E9C2F8C8C11

Q40718678-40FF44B7-92BD-4786-AB07-5790761EA950

Q40718678-4BCB2F9B-BF61-4B5D-AD8D-6618EB3D458C

Q40718678-4E78F901-8C19-4E47-BA48-7AAA11DD3F1C

Q40718678-4EF92782-DD28-46F2-920B-093E2AC31067

P304

Q40718678-2E7958C7-1352-48A0-B6CE-A15C6B7ADD73

P31

Q40718678-500D655B-2474-40B5-822B-C9A602616B35

P356

Q40718678-D0AFAD2C-414D-429E-9091-55A6BB9E52D0

P433

Q40718678-3AED84B8-72DE-48F7-9E77-D2FCABD0713B

P478

Q40718678-DBDF864C-B94F-4FAC-BE04-EE6E5D5FF5BB

P577

Q40718678-E581AF0D-5609-4272-BD0E-43DACF9F1EA2

P5875

Q40718678-77D1A697-125D-48F1-8EB2-FA2F75658086

P698

Q40718678-9484301F-CBBD-4756-BE32-209E5DC6D208

P921

Q40718678-8CE5B347-F18B-49BB-9AE0-750EC37C96B3

P356

P1433

International Journal of Cancer

P1476

Rat Muc4 (sialomucin complex) ...... nism for herceptin resistance.

@en

P2093

Kermit L Carraway

http://www.w3.org/2001/XMLSchema#string

Lisa Yee

http://www.w3.org/2001/XMLSchema#string

Maria Arango

http://www.w3.org/2001/XMLSchema#string

Peter Li

http://www.w3.org/2001/XMLSchema#string

Philip S Rudland

http://www.w3.org/2001/XMLSchema#string

Scott Jepson

http://www.w3.org/2001/XMLSchema#string

Shari A Price-Schiavi

http://www.w3.org/2001/XMLSchema#string

P2860

Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

Post-transcriptional regulation of a milk membrane protein, the sialomucin complex (Ascites sialoglycoprotein (ASGP)-1/ASGP-2, rat muc4), by transforming growth factor beta

An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling

Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.

Topology of cell adhesion molecules

P304

783-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.10410

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11264171

http://www.w3.org/2001/XMLSchema#string

P698

12115478

http://www.w3.org/2001/XMLSchema#string

P921